Journal of Advanced Biotechnology and Experimental Therapeutics (Aug 2023)

Oncogenic driver mutations in Vietnamese patients with lung adenocarcinoma

  • Linh Dieu Vuong,
  • Quang Ngoc Nguyen

DOI
https://doi.org/10.5455/jabet.2023.d136
Journal volume & issue
Vol. 6, no. 2
pp. 412 – 418

Abstract

Read online

Mutation profiles of oncogenes play essential roles in cancer therapy, but data on the prevalence of lung cancer oncogenic driver mutations in Vietnamese patients are limited. This study aims to evaluate the mutation status of EGFR, ALK, ROS1, RET and MET and analyze the association of gene mutations with clinicopathological characteristics of lung adenocarcinoma. Of the 179 lung adenocarcinoma tissues, EGFR, ALK, ROS1, RET and MET mutation frequencies were 44.6; 7.9; 3.0; 3.0 and 2.0 percent, respectively. EGFR, ALK, ROS1 and RET alterations tended to be higher in females. Moreover, rearrangements of ALK, ROS and RET were more prevalent in younger lung adenocarcinoma, but skipping at exon 14 MET was more frequent in male and older patients. Stages III and IV seem to accumulate more ALK, RET and MET abnormalities. These findings identified the variation of frequencies of Vietnamese lung adenocarcinoma with different clinicopathological characteristics and established the pioneer data for oncogenic diver mutation of lung cancer in Vietnam. [ J Adv Biotechnol Exp Ther 2023; 6(2.000): 412-418]

Keywords